Newron Pharmaceuticals
Biotechnology Research • 
Bresso, Lombardy, Italy • 21-50 Employees
Company overview
| Headquarters | Via Antonio Meucci, 3, Bresso, Lombardy 20091, IT |
| Phone number | +39026103461 |
| Website | |
| SIC | 873 |
| Keywords | Pharmaceuticals, Rare Diseases, Drug Development, Central Nervous System, CNS |
| Founded | 1999 |
| Employees | 21-50 |
| Socials |
Key Contacts at Newron Pharmaceuticals
Guy Gloor
Senior Director Cmc
Stefan Weber
Ceo, Managing Director
Arianna Baldo
Ceo Assistant
Newron Pharmaceuticals Email Formats
Newron Pharmaceuticals uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@newron.com), used 60% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@newron.com | 60% |
{first name}.{last name} | john.doe@newron.com | 40% |
About Newron Pharmaceuticals
Newron is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain. We are committed to delivering innovative treatments to improve the quality of life for patients with CNS disorders. Our team has built a balanced and robust pipeline comprised of drug candidates at different clinical stages and has a proven track record of drug development and commercialization. Xadago® (safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union and Switzerland (both 2015) as well as in the U.S. (2017) and is commercialized in Europe by Newron’s Partner Zambon. Supernus Pharmaceuticals holds the commercialization rights in the US. Valeo Pharma holds the commercialization rights for the Canadian market, Seqirus for Australia & New Zealand, and Medison for Israel. Meiji Seika, in collaboration with Eisai, has the rights to develop and commercialize the compound in Japan and other key Asian territories. In addition to Xadago® for Parkinson’s disease, Newron has a strong pipeline of promising treatments including Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia and ralfinamide for patients with specific rare pain indications. Founded in 1999, Newron is headquartered in Bresso, near Milan, Italy, with a subsidiary in Morristown, NJ, USA. The Company is listed on the SIX Swiss Exchange, under the trading symbol NWRN, on the primary market of the Düsseldorf Stock Exchange and on XETRA, trading symbol NP5.
Newron Pharmaceuticals revenue & valuation
| Annual revenue | $6,458,110 |
| Revenue per employee | $249,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $20,700,000 |
| Total funding | $27,900,000 |
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Newron Pharmaceuticals has 15 employees across 6 departments.
Departments
Number of employees
Newron Pharmaceuticals Tech Stack
Discover the technologies and tools that power Newron Pharmaceuticals's digital infrastructure, from frameworks to analytics platforms.
CDN
Security
Analytics
JavaScript libraries
JavaScript libraries
CMS
JavaScript libraries
Maps
JavaScript libraries
CDN
JavaScript libraries
Saudi Arabia
United Kingdom
Israel
Finland
Australia
Frequently asked questions
4.8
40,000 users
